Tsao L, Crosby E, Trotter T, Agarwal P, Hwang B, Acharya C, et al. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. JCI Insight. 2019;4: pubmed publisher

Engelbertsen D, Autio A, Verwilligen R, Depuydt M, Newton G, Rattik S, et al. Increased lymphocyte activation and atherosclerosis in CD47-deficient mice. Sci Rep. 2019;9:10608 pubmed publisher

Kojima Y, Werner N, Ye J, Nanda V, Tsao N, Wang Y, et al. Proefferocytic Therapy Promotes Transforming Growth Factor-? Signaling and Prevents Aneurysm Formation. Circulation. 2018;137:750-753 pubmed publisher

Kojima Y, Volkmer J, McKenna K, Civelek M, Lusis A, Miller C, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. 2016;536:86-90 pubmed

Willingham S, Volkmer J, Gentles A, Sahoo D, Dalerba P, Mitra S, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109:6662-7 pubmed publisher

Han X, Sterling H, Chen Y, Saginario C, Brown E, Frazier W, et al. CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem. 2000;275:37984-92 pubmed